Internal Reference Number: FOI_8254
Date Request Received: 05/11/2024 00:00:00
Date Request Replied To: 08/11/2024 00:00:00
This response was sent via: By Email
Request Summary: Urothelial cancer (any stage)
Request Category: Private Individuals
| Question Number 1: How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Other active systemic anti-cancer therapy Palliative care only | |
| Answer To Question 1: N/A 鈥� patients are referred to UHS for these types of treatment. We do treat patients with urothelial cancer but if they get metastatic disease they go to Southampton to see the oncology team there. The Trust therefore do not use any of the treatments above. | |
| Question Number 2: Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part? | |
| Answer To Question 2: No | |
| To return to the list of all the FOI requests please click here |
Our staff at 黑料网 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
